Clenbuterol exerts antidiabetic activity through metabolic reprogramming of skeletal muscle cells
Research output: Contribution to journal › Journal article › Research › peer-review
- Meister et al_Nature Communications_2022_Vol 13_e22
Final published version, 2.73 MB, PDF document
Activation of the sympathetic nervous system causes pronounced metabolic changes that are mediated by multiple adrenergic receptor subtypes. Systemic treatment with β2-adrenergic receptor agonists results in multiple beneficial metabolic effects, including improved glucose homeostasis. To elucidate the underlying cellular and molecular mechanisms, we chronically treated wild-type mice and several newly developed mutant mouse strains with clenbuterol, a selective β2-adrenergic receptor agonist. Clenbuterol administration caused pronounced improvements in glucose homeostasis and prevented the metabolic deficits in mouse models of β-cell dysfunction and insulin resistance. Studies with skeletal muscle-specific mutant mice demonstrated that these metabolic improvements required activation of skeletal muscle β2-adrenergic receptors and the stimulatory G protein, Gs. Unbiased transcriptomic and metabolomic analyses showed that chronic β2-adrenergic receptor stimulation caused metabolic reprogramming of skeletal muscle characterized by enhanced glucose utilization. These findings strongly suggest that agents targeting skeletal muscle metabolism by modulating β2-adrenergic receptor-dependent signaling pathways may prove beneficial as antidiabetic drugs.
|Number of pages||14|
|Publication status||Published - 2022|
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Number of downloads are based on statistics from Google Scholar and www.ku.dk